Medidata Solutions Inc  

(Public, NASDAQ:MDSO)   Watch this stock  
72.99
+1.12 (1.56%)
Real-time:   2:05PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 71.40 - 73.03
52 week 41.65 - 73.15
Open 71.88
Vol / Avg. 222,664.00/467,815.00
Mkt cap 4.21B
P/E 128.48
Div/yield     -
EPS 0.57
Shares 58.36M
Beta 1.59
Inst. own 106%
Jul 18, 2017
Q2 2017 Medidata Solutions Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 1, 2017
Medidata Solutions Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 30, 2017
Medidata Solutions Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 22, 2017
Medidata Solutions Inc at JPMorgan Tech, Media and Telecom Conference - Webcast
May 16, 2017
Medidata Solutions Inc at Needham Emerging Technology Conference
May 9, 2017
Medidata Solutions Inc at Jefferies Technology Conference
Apr 26, 2017
Q1 2017 Medidata Solutions Inc Earnings Release
Apr 26, 2017
Q1 2017 Medidata Solutions Inc Earnings Call - Webcast
Mar 1, 2017
Medidata Solutions Inc at Morgan Stanley Technology, Media & Telecom Conference
Feb 27, 2017
Medidata Solutions Inc at JMP Securities Technology Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 7.51% 6.25%
Operating margin 9.60% 10.84%
EBITD margin - 14.15%
Return on average assets 4.64% 3.86%
Return on average equity 9.39% 8.45%
Employees 1,424 -
CDP Score - -

Address

350 Hudson St Fl 9
NEW YORK, NY 10014-4535
United States - Map
+1-212-9181800 (Phone)
+1-212-9181818 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medidata Solutions Inc. (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company's plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments. Study Design Optimization enables customers to gain visibility into the impact of protocol elements on resource and trial endpoints. Grants Manager compares specific industry benchmarks and analytics, using industry's database of negotiated procedure costs, to support appropriate grants to investigator sites and automated negotiations with multiple investigator sites. Payments enables customers to establish a global investigator payment strategy and process to automate payment calculation, distribution and reporting, including tax and currency exchange calculations.

Officers and directors

Tarek A. Sherif Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Glen M. de Vries President, Director
Age: 44
Bio & Compensation  - Reuters
Rouven Bergmann Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Michael L. Capone Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Michael I. Otner Executive Vice President, General Counsel, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Michael Christopher Pray Executive Vice President, General Manager - Global Sales
Age: 51
Bio & Compensation  - Reuters
Mary Weger Executive Vice President—Human Resources
Age: 58
Bio & Compensation  - Reuters
Carlos Dominguez Independent Director
Age: 58
Bio & Compensation  - Reuters
Neil M. Kurtz M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
George W. McCulloch Independent Director
Age: 40
Bio & Compensation  - Reuters